Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

Inclusion Criteria: Adult patients (greater than 18 years of age) with glioma who require MRI and ¹⁸FDG-PET imaging. Exclusion Criteria: Pregnant or breastfeeding. Adults lacking capacity to consent not will be included in this study. All other vulnerable populations - children, pregnant women, and prisoners - will not be included. Contraindication to PET, MRI, ¹⁸FDG or intravenous gadolinium-based contrast agents. Claustrophobia. Weight greater than modality maximum capacity. Presence of metallic foreign body or implanted medical devices in body not documented as MRI safe according to the OHSU Department of Radiology Guidelines (including but not limited to cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants). Sickle cell disease. Reduced renal function, as determined by GFR < 45 mL/min/1.73 m2 based on a serum creatinine level obtained per OHSU Department of Radiology and OHSU Advanced Imaging Research Center (AIRC) clinical criteria. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ¹⁸FDG. Unsure of pregnancy status as assessed by Department of Radiology and AIRC guidelines. Presence of any other co-existing condition that, in the judgment of the principal investigator, might increase the risk to the subject. Poor peripheral intravenous access evaluated by patient history. Presence of other serious systemic illnesses, including: uncontrolled infection, other uncontrolled malignancy, uncontrolled diabetes type II, or psychiatric/social situations which might impact the endpoint of the study or limit compliance with study requirements.